Cantor Fitzgerald Estimates MRK FY2025 Earnings

Merck & Co., Inc. (NYSE:MRK - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Merck & Co., Inc. in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen expects that the company will post earnings of $9.55 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $155.00 price target on the stock. The consensus estimate for Merck & Co., Inc.'s current full-year earnings is $7.70 per share.

A number of other equities analysts have also recently issued reports on the stock. Barclays cut their price objective on shares of Merck & Co., Inc. from $142.00 to $140.00 and set an "overweight" rating on the stock in a research report on Monday, October 7th. Daiwa Capital Markets downgraded shares of Merck & Co., Inc. from a "buy" rating to a "neutral" rating in a report on Monday, November 11th. UBS Group reduced their price objective on shares of Merck & Co., Inc. from $125.00 to $120.00 and set a "buy" rating for the company in a report on Wednesday, January 8th. Wells Fargo & Company decreased their target price on shares of Merck & Co., Inc. from $125.00 to $110.00 and set an "equal weight" rating for the company in a research report on Friday, November 1st. Finally, Leerink Partners dropped their price target on shares of Merck & Co., Inc. from $136.00 to $119.00 and set an "outperform" rating on the stock in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, eight have given a hold rating, nine have given a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. has an average rating of "Moderate Buy" and an average price target of $123.00.

Merck & Co., Inc. Trading Up 0.9 %

Shares of MRK stock traded up $0.89 during trading hours on Wednesday, hitting $96.57. 11,512,593 shares of the company were exchanged, compared to its average volume of 10,553,397. The company has a 50 day simple moving average of $99.85 and a two-hundred day simple moving average of $109.11. The firm has a market cap of $244.28 billion, a P/E ratio of 20.24, a P/E/G ratio of 1.13 and a beta of 0.39. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. Merck & Co., Inc. has a fifty-two week low of $94.48 and a fifty-two week high of $134.63.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $1.57 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.07. Merck & Co., Inc. had a return on equity of 36.42% and a net margin of 19.23%. The firm had revenue of $16.66 billion during the quarter, compared to the consensus estimate of $16.47 billion. During the same period last year, the business posted $2.13 EPS. The business's revenue was up 4.4% compared to the same quarter last year.

Merck & Co., Inc. Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 8th. Stockholders of record on Monday, December 16th were issued a $0.81 dividend. This represents a $3.24 annualized dividend and a dividend yield of 3.36%. The ex-dividend date was Monday, December 16th. This is an increase from Merck & Co., Inc.'s previous quarterly dividend of $0.77. Merck & Co., Inc.'s payout ratio is 67.92%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MRK. Mountain Pacific Investment Advisers LLC boosted its holdings in shares of Merck & Co., Inc. by 2.2% in the 3rd quarter. Mountain Pacific Investment Advisers LLC now owns 4,541 shares of the company's stock valued at $516,000 after buying an additional 96 shares in the last quarter. Constitution Capital LLC grew its holdings in Merck & Co., Inc. by 2.1% in the third quarter. Constitution Capital LLC now owns 4,950 shares of the company's stock worth $562,000 after purchasing an additional 100 shares during the last quarter. E&G Advisors LP increased its position in shares of Merck & Co., Inc. by 0.7% during the third quarter. E&G Advisors LP now owns 14,698 shares of the company's stock worth $1,669,000 after purchasing an additional 100 shares in the last quarter. Massachusetts Wealth Management lifted its holdings in shares of Merck & Co., Inc. by 0.4% during the 3rd quarter. Massachusetts Wealth Management now owns 22,474 shares of the company's stock valued at $2,552,000 after purchasing an additional 100 shares during the last quarter. Finally, Shayne & Jacobs LLC boosted its position in shares of Merck & Co., Inc. by 1.8% in the 3rd quarter. Shayne & Jacobs LLC now owns 5,611 shares of the company's stock worth $637,000 after purchasing an additional 100 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.